2025-12-31 - Analysis Report
Okay, let's break down the analysis of Merck & Co. (MRK).

**0) Overview and Data Presentation**

We'll present the simple numbers first, then add analysis based on those numbers.

**1) Return Rate Comparison**

*   **MRK Company Overview:** Merck & Co. Inc. is a global pharmaceutical company.
*   **MRK Cumulative Return:** 26.16%
*   **S&P 500 (VOO) Cumulative Return:** 102.21%
*   **Divergence:**
    *   Max: 23.9
    *   Min: -104.3
    *   Current: -76.2
    *   Relative Divergence: 21.9

**Analysis:**  MRK has significantly underperformed the S&P 500 over the observed period. The divergence is quite large, indicating a substantial difference in returns. The relative divergence of 21.9 suggests that the current divergence is near the lower end of its historical range.

**Alpha, Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 1.0% | 68.5% | -28.0% | 0.0 | 134.1 |
| 2016-2018  | 36.0% | 69.8% | 21.0% | -0.0 | 182.1 |
| 2017-2019  | 40.0% | 69.8% | 18.0% | 0.3 | 216.8 |
| 2018-2020  | 16.0% | 79.6% | -8.0% | 0.3 | 195.0 |
| 2019-2021  | 2.0% | 79.6% | -44.0% | 0.7 | 191.4 |
| 2020-2022  | 15.0% | 79.6% | 16.0% | 0.7 | 277.1 |
| 2021-2023  | 33.0% | 79.6% | 31.0% | 0.3 | 272.3 |
| 2022-2024  | -4.0% | 79.6% | -25.0% | 0.2 | 248.5 |
| 2023-2025  | -23.0% | 71.5% | -90.0% | 1.8 | 264.9 |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):** Fluctuates significantly.  Recent years (2022-2025, 2023-2025) show negative growth.
*   **MDD (Maximum Drawdown):** High drawdowns, suggesting significant risk.
*   **Alpha:**  Periods of both positive and negative alpha.  The most recent period shows a very large negative alpha, indicating substantial underperformance relative to the market.
*   **Beta:**  Generally low, suggesting the stock is less sensitive to market movements than the S&P 500. However, 2023-2025 shows a significantly increased Beta, indicating a strong correlation.
*   **Cap(B) (Capitalization in Billions):**  Shows growth and then some fluctuations in the later periods.

**2) Recent Stock Price Fluctuations**

*   **Close:** 106.06
*   **Last-market:** {'price': 106.06, 'previousClose': 106.62, 'change': -0.53}
*   **5-day SMA:** 106.19
*   **20-day SMA:** 101.633
*   **60-day SMA:** 93.88

**Analysis:** The stock price is currently slightly below its 5-day SMA but significantly above both the 20-day and 60-day SMAs. This indicates a recent uptrend. The last market data shows a small decrease.

**3) RSI, PPO, and Expected Return**

*   **MRI:** 0.9 (High Investment Recommended)
*   **RSI:** 81.25 (Overbought)
*   **PPO:** 0.254
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (2 shares - Very Safe - MRI:0.90)
*   **Recent (20 days) relative divergence change:** 2.4 (+) (Short-term rise)
*   **Expected Return (%):** -39.6

**Analysis:**

*   The MRI suggests a high investment recommendation, but the RSI indicates overbought conditions.
*   The PPO is slightly positive, supporting the uptrend idea.
*   The Hybrid Signal suggests a "Buy" recommendation.
*   The negative expected return is concerning, suggesting potential underperformance in the long term.

**4) Recent News & Significant Events**

*   **Positive Headlines:** "Why Merck (MRK) is a Top Value Stock for the Long-Term," "Merck: A Post-2028 Slowdown Doesn’t Kill The Long-Term Thesis," "How Does Merck Stock Stack Up Against Its Peers?"
*   **Mixed/Cautious Headlines:** "Merck (MRK) Stock Today: Latest News, Analyst Forecasts, and What Investors Should Watch Before Monday’s Open," "Is Merck Stock’s Run Legitimate?"
*   **Negative Headlines:** "Farmers & Merchants Investments Inc. Cuts Stock Position in Merck & Co., Inc."

**Analysis:** The news sentiment is mixed. Some articles highlight long-term value, while others express caution or report stock position reductions.  The "Post-2028 Slowdown" article is particularly important – it suggests a potential future challenge for the company.

**4-2) Analyst Opinions**

*   **Consensus:** Buy (Mean: 1.90)
*   **Target Price (avg/high/low):** 110.04 / 139.00 / 83.00

**Analysis:**  Analysts generally have a "Buy" rating on the stock. The average target price suggests a potential upside from the current price. The range of target prices is wide, indicating varying degrees of optimism among analysts.  The lack of specific recent rating changes makes it difficult to assess the current trend in analyst sentiment.

**5) Recent Earnings Analysis**

| 날짜       | EPS  | 매출      |
|------------|------|-----------|
| 2025-11-05 | 2.32 | 17.28 B$  |
| 2025-08-05 | 1.76 | 15.81 B$  |
| 2025-05-02 | 2.01 | 15.53 B$  |
| 2024-11-06 | 1.25 | 16.66 B$  |
| 2025-11-05 | 1.25 | 16.66 B$  |

**Analysis:**  EPS and Revenue show some growth from 2024 to 2025, but the final entry appears to be a duplicate. However, the trend generally shows increasing revenue, suggesting a healthy business overall.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30   | $17.28B  | 77.69%        |
| 2025-06-30   | $15.81B  | 77.50%        |
| 2025-03-31   | $15.53B  | 77.98%        |
| 2024-12-31   | $15.62B  | 75.50%        |
| 2024-09-30   | $16.66B  | 75.51%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE   |
|--------------|-----------|-------|
| 2025-09-30   | $51.85B  | 11.16% |
| 2025-06-30   | $48.99B  | 9.04%  |
| 2025-03-31   | $48.34B  | 10.51% |
| 2024-12-31   | $46.31B  | 8.08%  |
| 2024-09-30   | $44.50B  | 7.09%  |

**Analysis:**

*   **Revenue:**  Shows an increasing trend.
*   **Profit Margin:**  Very high and relatively stable, indicating strong pricing power and cost control.
*   **Equity:** Growing, reflecting retained earnings and potentially other capital infusions.
*   **ROE (Return on Equity):** Improving trend, indicating increasing profitability relative to equity.

**7) Comprehensive Analysis**

*   **Underperformance vs. S&P 500:** MRK has significantly underperformed the S&P 500, and Alpha figures confirm a lack of outperformance.
*   **Mixed Signals:** The MRI and Hybrid Signal are positive, while the RSI suggests overbought conditions.
*   **Positive Momentum:** Recent stock price movement and analyst ratings suggest positive short-term momentum.
*   **Long-Term Concerns:** The negative expected return and the mention of a "Post-2028 Slowdown" raise concerns about long-term growth prospects.
*   **Strong Financials:** High profit margins, growing revenue, increasing equity, and improving ROE are positive indicators of the company's financial health.
*   **News Sentiment:** A mixed bag of news headlines, with some focusing on value and others expressing caution.

**Overall Recommendation:**

The analysis presents a mixed picture. While MRK exhibits strong financial performance and positive recent momentum, significant long-term underperformance compared to the market and potential future challenges warrant caution. Investors should weigh the positive short-term indicators against the longer-term risks. The negative expected return is a significant red flag that needs further investigation.

Therefore, a **HOLD** or a small **BUY** position with a close watch on the "Post-2028 Slowdown" and long-term expected returns, based on future earnings reports.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.